July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Nine-year treatment outcome of naïve polypoidal choroidal vasculopathy in clinical practice
Author Affiliations & Notes
  • Byung Ju Jung
    Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of)
  • Won Ki Lee
    Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Byung Ju Jung, None; Won Ki Lee, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2403. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Byung Ju Jung, Won Ki Lee; Nine-year treatment outcome of naïve polypoidal choroidal vasculopathy in clinical practice. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2403. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the nine-year treatment outcomes of naïve polypoidal choroidal vasculopathy (PCV)

Methods : Fourty-seven treatment-naïve PCV eyes were reviewed retrospectively. Initial treatment was photodynamic therapy (PDT) alone or PDT combined with anti-vascular endothelial growth factor (VEGF), and adjuvant anti-VEGF or PDT was applied based on recurrence or retreatment criteria. The main outcome measures were best-corrected visual acuity (BCVA) and number of anti-VEGF injections at each year. We also conducted the distribution of BCVA into 3 groups: improved BCVA≥0.3 logMAR, deteriorated BCVA≥0.3 logMAR, and stable BCVA. Furthermore, we divided in 3 groups regarding as the number of PDT sessions: group A (PDT=1), group B (PDT=2), and group C (PDT≥3).

Results : The total mean±SD logMAR BCVA at baseline and year 1, 2, and 9 were 0.49±0.32, 0.30±0.29, 0.38±0.38 and 0.63±0.47, respectively. Significant improvements were observed at year 1 and 2 compared with baseline mean BCVA (p<.001, p =.046, respectively). The means of BCVA change at year 9 were improvement of 0.15 logMAR in the group A, decline of 0.23 logMAR in the group B, and decline of 0.46 logMAR in the group C (p<.001). The total mean number of injections during 9 years were 21.6±14.3 in total, 16.1±9.8 in the group A, 21.9±11.0 in the group B, and 29.0±19.1 in the group C (p=.04). The percentages of improved or stable eye at ninth year were 61.7% in total, 78.9% in the group A, 57.1% in the group B, and 42.8% in the group C (p =.01). 93.6% showed recurrence for the follow-up periods.

Conclusions : Although most PCV eyes experienced recurrence, nine-year prognosis of well treated PCV showed favorable visual outcomes. PDT is a good treatment option, but minimizing a total number of PDT sessions is important for final outcomes.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×